|Articles|September 7, 2022

New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials

IQVIA announced new evidence that decentralized clinical trials (DCTs) deliver measurable benefits for patients, sites, and sponsors.

In this analysis decentralized trials were assessed against 14 metrics across three categories—productivity, quality, and trial delivery, to determine how a DCT approach compared to traditional study models. The analysis found that sponsors can achieve faster, less expensive, and more engaging trials using DCT driven protocols.

Related to this article

October 29th, 2026

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.

October 29th, 2026

How Embedding Research Into Routine Community Care Changes Who Gets Access

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.

October 29th, 2026

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.

© putilov_denis - © putilov_denis - stock.adobe.com

October 28th, 2026

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.

October 28th, 2026

What It Would Take to Make Community Trials Accessible and Scalable

In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.

October 28th, 2026

ACT Brief: Legacy Trial Workflows, Medical Writing Talent Gaps, and Post-Exposure COVID Prevention

In today’s ACT Brief, we examine how legacy workflows pull community clinics away from patient care, why medical writing capacity depends on training rather than technology, and how an antiviral aims to prevent COVID-19 after exposure

October 27th, 2026

Closing the Medical Writing Capacity Gap: Why Training Beats Technology

Medical writing capacity pressure is fundamentally a talent development problem, not a technology problem, since hybrid resourcing and AI cannot substitute for the experienced judgment needed to review AI output and mentor the next generation of writers.

October 27th, 2026

Why Legacy Trial Workflows Weigh So Heavily on Community and Rural Clinics

In this video interview, Kent Thoelke, CEO of Paradigm Health, describes how manual eligibility screening and swivel-chair data entry force community sites to trade billable patient care for research, and why that burden is so hard to absorb.